VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
REGNRegeneron Pharmaceuticals, Inc.
$609.94$63.4B
Research
OverviewAnalysis
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksREGNPrice Target
REGN logo

Regeneron Pharmaceuticals, Inc. (REGN) Price Target Analysis

Updated Jun 18, 2026
Analyst Rating: Buy
Based on 48 analysts

37.1% Below Target

REGN trades 37.1% below Wall Street's consensus target of $836.00.

Current Price$609.94
Average Target$836.00
Target
Current
Low$641.00
Median$857.50
High$995.00

Analyst Target Range

Forward P/E13.1x
(Value)
PEG Ratio2.07
(Pricey)
Implied Growth+13.1%
(Moderate)
Analyst Spread42.3%
(Moderate)

Price Forecast (1 Year)

Last 12 months price action with 12-month analyst target path

Current$609.94
Consensus$836.00
High$995.00
Low$641.00

Consensus Scenario Assumptions

The base valuation assumes REGN achieves its forward estimates and maintains a stable P/E multiple of 13.1x. This scenario reflects the blended consensus of 48 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.

Analyst Ratings Distribution

Breakdown of 48 published analyst recommendations for REGN

32/48 analysts are bullish
+33
BearishBullish
Weighted analyst sentiment score based on 48 ratings
ConsensusBuy
Coverage48 Analysts
Net Score+33
Bull / Bear67% / 0%
Strong Buy00%
Buy3267%
Hold1633%
Sell00%
Strong Sell00%
Strong Buy
00%
Buy
3267%
Hold
1633%
Sell
00%
Strong Sell
00%
Recommendation Mix67% Buy · 33% Hold · 0% Sell
Buy (32)Hold (16)Sell (0)

REGN Price Target Analysis

Updated June 21, 2026

As of June 21, 2026, Regeneron Pharmaceuticals, Inc. (REGN) has a Wall Street consensus price target of $836.00, based on estimates from 48 covering analysts. With the stock currently trading at $609.94, this represents a potential upside of +37.1%. The company has a market capitalization of $63.37B.

Analyst price targets range from a low of $641.00 to a high of $995.00, representing a 42% spread in expectations. The median target of $857.50 aligns closely with the consensus average.

The current analyst consensus rating is Buy, with 32 analysts rating the stock as a Buy or Strong Buy,16 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.

From a valuation perspective, REGN trades at a trailing P/E of 14.7x and forward P/E of 13.1x. The forward PEG ratio of 2.07 reflects a premium valuation. Analysts expect EPS to grow +13.1% over the next year.

Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $812.16, with bear and bull scenarios of $511.66 and $1070.10 respectively. Model confidence stands at 57/100, reflecting moderate uncertainty in projections.

Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.

Analyst Sentiment Comparison

Industry Peer Analysis
Avg Peer Upside
+20.0%
Industry Consensus
Avg Forward P/E
16.9x
(Fair)
Peers with Coverage
10 / 10
Active Analyst Tracking
CompanyMarket CapPriceTargetUpside PotentialRatingFwd P/EAnalysts
BIIB logo
BIIBBiogen Inc.
$29.0B$196.58$218.32
+11.1%
Buy13.5x48
VRTX logo
VRTXVertex Pharmaceuticals Incorporated
$114.9B$451.63$553.93
+22.7%
Buy23.4x56
INCY logo
INCYIncyte Corporation
$19.6B$98.22$109.80
+11.8%
Buy13.0x44
BMRN logo
BMRNBioMarin Pharmaceutical Inc.
$10.5B$54.69$89.93
+64.4%
Buy11.1x41
ABBV logo
ABBVAbbVie Inc.
$383.2B$216.63$256.92
+18.6%
Buy15.2x41
LLY logo
LLYEli Lilly and Company
$1.0T$1098.13$1271.24
+15.8%
Buy30.0x45
AMGN logo
AMGNAmgen Inc.
$182.2B$337.60$349.33
+3.5%
Buy15.1x38
GILD logo
GILDGilead Sciences, Inc.
$153.7B$123.76$161.81
+30.7%
Buy—58
MRK logo
MRKMerck & Co., Inc.
$281.2B$113.87$131.58
+15.6%
Buy22.2x37
PFE logo
PFEPfizer Inc.
$143.5B$25.22$26.75
+6.1%
Hold8.5x39

REGN — Frequently Asked Questions

Quick answers to the most common questions about buying REGN stock.

What is the REGN stock price target for 2026?

The consensus Wall Street price target for REGN is $836, representing 37.1% upside from the current price of $609.94. With 48 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.

Is REGN a buy, sell, or hold?

REGN has a consensus rating of "Buy" based on 48 Wall Street analysts. The rating breakdown is predominantly bullish, with 32 Buy/Strong Buy ratings. The consensus 12-month price target of $836 implies 37.1% upside from current levels.

Is REGN stock overvalued or undervalued?

With a forward P/E of 13.1285x, REGN trades at a relatively low valuation. The consensus target of $836 implies 37.1% appreciation, suggesting meaningful undervaluation.

How high can REGN stock go?

The most bullish Wall Street analyst has a price target of $995 for REGN, while the most conservative target is $641. The consensus of $836 represents the median expectation. Our quantitative valuation model projects a bull case target of $1070 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

How many analysts cover REGN stock?

REGN is heavily covered by Wall Street, with 48 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 32 have Buy ratings, 16 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

What is the REGN stock forecast?

The 12-month REGN stock forecast based on 48 Wall Street analysts shows a consensus price target of $836, with estimates ranging from $641 (bear case) to $995 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $812, with bear/bull scenarios of $512/$1070.

What is REGN's fair value based on fundamentals?

Our quantitative valuation model calculates REGN's fair value at $812 (base case), with a bear case of $512 and bull case of $1070. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 57/100.

What is REGN's forward P/E ratio?

REGN trades at a forward P/E ratio of 13.1x based on next-twelve-months earnings estimates compared to a trailing P/E of 14.7x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

Should I buy REGN stock?

Wall Street analysts are very optimistic on REGN, with a "Buy" consensus rating and $836 price target (37.1% upside). 32 of 48 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

Why do REGN price targets vary so much?

REGN analyst price targets range from $641 to $995, a 42% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $836 consensus represents the middle ground. Our model's $512-$1070 range provides an independent fundamental perspective.

Consensus-Based Analysis Tools

Full Stock Analysis

Deep dive into REGN consensus models and risk factors.

View Analysis

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare